BioDrugs

, Volume 15, Issue 4, pp 261–278

Risk Factors for and Management of Post-Transplantation Cardiovascular Disease

Review Article

Abstract

The mortality rates due to cardiovascular disease (CVD) in transplant recipients are greater than in the general population. CVD is a major cause of both graft loss and patient death in renal transplant recipients, and improving cardiovascular health in transplant recipients will presumably help to extend both patient and graft survival. Further studies are needed to better evaluate the effectiveness of risk modification on subsequent CVD morbidity and mortality.

There is no reason to consider risk factors for CVD such as hyperlipidaemia, hypertension and diabetes mellitus in transplant recipients differently from in the general population. In addition, there are specific transplantation risk factors such as acute rejection episodes and the use of immunosuppressive drugs. It is obvious that several of the immunosuppressive agents used today have disadvantageous influences on risk factors for CVD such as hyperlipidaemia, hypertension and post-transplantation diabetes mellitus (PTDM), but the relative importance of immunosuppressant-induced increases in these risk factors is basically unknown. This may be a strong argument for the selective use and individual tailoring of immunosuppressive agents based upon the risk factor profile of the patient, without jeopardising the function of the graft.

Hyperlipidaemia is common after transplantation, and immunosuppression with corticosteroids, cyclosporin, or sirolimus (rapamycin) causes different types of post-transplantation hyperlipidaemia. However, to date, no studies have demonstrated that lipid lowering strategies significantly reduce CVD morbidity or mortality and improve allograft survival in transplant recipients. Several studies using preventive or interventional approaches are ongoing and will be reported in the near future.

Post-transplantation hypertension appears to be a major risk factor determining graft and patient survival, and immunosuppressive agents have different effects on hypertension. Controlled studies support the opinion that post-transplantation hypertension must be treated as strictly as in a population with essential hypertension, diabetes mellitus, or chronic renal failure.

As increasing numbers of immunosuppressive agents become available for use, we may be in a better position to tailor immunosuppressive therapy to the individual patient, avoiding the use of diabetogenic drugs, drug combinations, or inappropriate doses in patients susceptible to PTDM.

Multiple acute rejection episodes have also been demonstrated to be a risk factor for CVD — a strong argument for the use of immunosuppressive drugs to reduce acute rejection.

Until we have a better understanding from ongoing landmark studies on the management of CVD, presently available therapy to reduce risk factors needs to be used together with individual tailoring of immunosuppressive therapy with the aim of reducing CVD in these patients.

References

  1. 1.
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32Suppl. 3: S112–9PubMedCrossRefGoogle Scholar
  2. 2.
    Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158–65PubMedGoogle Scholar
  3. 3.
    Johnson DW, Herzig K, Purdie D, et al. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation 2000; 69: 794–9PubMedCrossRefGoogle Scholar
  4. 4.
    Rabbat CG, Thorpe KE, Russell JD, et al. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11: 917–22PubMedGoogle Scholar
  5. 5.
    Schaubel D, Desmeules M, Mao Y, et al. Survival experience among elderly end-stage renal disease patients. A controlled comparison of transplantation and dialysis. Transplantation 1995; 60: 1389–94PubMedCrossRefGoogle Scholar
  6. 6.
    Cosio FG, Alamir A, Yim S, et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998; 53: 767–72PubMedCrossRefGoogle Scholar
  7. 7.
    Kavanagh D, Morris S, Northridge DB, et al. Electrocardiogram and outcome following renal transplantation. Nephron 1999; 81: 109PubMedCrossRefGoogle Scholar
  8. 8.
    Lindholm A, Albrechtsen D, Frödin L, et al. Ischemic heart disease — major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451–7PubMedCrossRefGoogle Scholar
  9. 9.
    USRDS Annual Report. Chapter 6: causes of death. Ann Arbor, MI: USRDS, 1999: 89–100. Available from: URL: http://www.usrds.org
  10. 10.
    Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853–906PubMedCrossRefGoogle Scholar
  11. 11.
    Jardine AG. Pretransplant management of end-stage renal disease patients to minimize posttransplant risk. Transplantation 2000; 70(11 Suppl.): SS46–50PubMedGoogle Scholar
  12. 12.
    De Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996; 7: 2044–54PubMedGoogle Scholar
  13. 13.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. n Eng J Med 1995; 333(20): 1301–7CrossRefGoogle Scholar
  14. 14.
    Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 32Suppl. 3: S142–56PubMedCrossRefGoogle Scholar
  15. 15.
    Jindal RM. Post-transplant hyperlipidaemia. Postgrad Med J 1997; 73: 785–93PubMedCrossRefGoogle Scholar
  16. 16.
    Keane WF. Derangement of lipid metabolism and its management in renal transplant patients. Miner Electrolyte Metab 1997; 23: 166–9PubMedGoogle Scholar
  17. 17.
    Aakhus S, Dahl K, Widerϕe TE. Hyperlipidaemia in renal transplant patients. J Intern Med 1996; 239: 407–15PubMedCrossRefGoogle Scholar
  18. 18.
    Segoloni GP, Triolo G, Cassader M, et al. Dyslipidemia in renal transplantation: a 3-year follow-up. Transplant Proc 1993; 25: 2178–9PubMedGoogle Scholar
  19. 19.
    Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5: 2073–81PubMedGoogle Scholar
  20. 20.
    Jung K, Scheifler A, Blank W, et al. Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation. Transplantation 1988; 46: 407–9PubMedCrossRefGoogle Scholar
  21. 21.
    Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 1987; 66: 309–16Google Scholar
  22. 22.
    Rao VK. Posttransplant medical complications. Surg Clin North Am 1998; 78: 113–32PubMedCrossRefGoogle Scholar
  23. 23.
    Hilbrands LB, Demacker PN, Hoitsma AJ. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993; 341: 765–6PubMedCrossRefGoogle Scholar
  24. 24.
    Brown JH, Anwar N, Short CD, et al. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporine monotherapy. Nephrol Dial Transplant 1993; 8: 863–7PubMedGoogle Scholar
  25. 25.
    Ghanem H, van den Dorpel MA, Weimar W, et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996; 49: 488–93PubMedCrossRefGoogle Scholar
  26. 26.
    Sutherland WH, Walker RJ, Ball MJ, et al. Oxidation of low density lipoproteins from patients with renal failure. Kidney Int 1995; 48: 227–36PubMedCrossRefGoogle Scholar
  27. 27.
    Apanay DC, Neylan JF, Ragab MS, et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994; 58: 663–9PubMedGoogle Scholar
  28. 28.
    Dasgupta K, Powell D, Saldana S, et al. Elevated lipid peroxidation products and depleted transferring levels in the plasma of kidney transplant recipients. Life Sci 1990; 46: 67–72PubMedCrossRefGoogle Scholar
  29. 29.
    Kasiske B. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1998; 84: 985–92CrossRefGoogle Scholar
  30. 30.
    Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648–54PubMedCrossRefGoogle Scholar
  31. 31.
    Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclsoporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37–43PubMedCrossRefGoogle Scholar
  32. 32.
    Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 1755–60PubMedCrossRefGoogle Scholar
  33. 33.
    Jindal RM, Sidner RA, Hughes DA, et al. Metabolic problems in recipients of liver transplants. Clin Transplant 1996; 10: 213–7PubMedGoogle Scholar
  34. 34.
    Hricik DE, Bartucci MR, Mayes JT, et al. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868–71PubMedCrossRefGoogle Scholar
  35. 35.
    Lopez-Miranda J, Perez-Jimenez F, Torres A, et al. Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992; 25: 379–86PubMedCrossRefGoogle Scholar
  36. 36.
    Raine AE, Carter R, Mann JI, et al. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 1988; 3: 458–63PubMedGoogle Scholar
  37. 37.
    Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53–6PubMedCrossRefGoogle Scholar
  38. 38.
    Schorn TF, Kliem V, Bojanovski M, et al. Impact of long-term immunosuppression with cyclosporine A on serum lipids in stable renal transplant recipients. Transplant Int 1991; 4: 92–5Google Scholar
  39. 39.
    Donahoo WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am 1998; 27: 677–97PubMedCrossRefGoogle Scholar
  40. 40.
    van den Dorpel MA, Ghanem H, Rischen-Vos J, et al. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997; 51: 1608–12PubMedCrossRefGoogle Scholar
  41. 41.
    Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998; 65: 446–9PubMedCrossRefGoogle Scholar
  42. 42.
    Jensik SC. Tacrolimus (FK506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216–8PubMedCrossRefGoogle Scholar
  43. 43.
    Claesson K, Mayer AD, Squifflet J-P, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients. Transplant Proc 1998; 30: 1292–4PubMedCrossRefGoogle Scholar
  44. 44.
    Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977–83PubMedCrossRefGoogle Scholar
  45. 45.
    Margreiter R. A prospective, randomized, multicentre study to compare the efficacy and safety of tacrolimus and ciclosporinmicroemulsion in renal transplantation. European Tacrolimus vs Ciclosporin-Microemulsion Renal Transplantation Study Group. Transplantation 2000; 69Suppl.: S112CrossRefGoogle Scholar
  46. 46.
    Johnson C, Ahsan N, Gonwa TA, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834–41PubMedCrossRefGoogle Scholar
  47. 47.
    Friemann S, Stopp K, Christi R, et al. Conversion to tacrolimus in hyperlipidemic patients. Transplant Proc 1999; 31Suppl. 7A: 41S–3SPubMedCrossRefGoogle Scholar
  48. 48.
    Short CD, Johnson RWG, Roberts IDS. Two years of tacrolimus monotherapy following renal transplantation [abstract]. 4th International Conference on New Trends in Clinical and Experimental Immunosuppression; 2000: 154Google Scholar
  49. 49.
    Bos JD, et al. A European, multicenter, randomized, doubleblind study to evaluate the safety and efficacy of FK506 (tacrolimus) in the treatment of severe, recalcitrant plaquetype psoriasis. Skin Pharmacol 1995; 8: 74Google Scholar
  50. 50.
    Fujisawa. Laboratory: blood chemistry. Report No.: FG-94-506-02. Supplementary Appendix 7. (Data on file)Google Scholar
  51. 51.
    Caldwell J. Efficacy of FK506 in rheumatoid arthritis (RA): dose-ranging study in RA patients failing methotrexate (MTX) [abstract]. 4th International Conference on New Trends in Clinical and Experimental Immunosuppression; 2000: 153Google Scholar
  52. 52.
    Fujisawa. Chemistry parameters. Report No.: L1999000037: 45–50 (Data on file)Google Scholar
  53. 53.
    Abouljoud MS, Levy MF, Klintmalm GB. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine US Multicenter trial. US Multicenter Study Group. Transplant Proc 1995; 27: 1121–3PubMedGoogle Scholar
  54. 54.
    Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994; 57: 1395–8PubMedCrossRefGoogle Scholar
  55. 55.
    Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036–42PubMedCrossRefGoogle Scholar
  56. 56.
    Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040–6PubMedCrossRefGoogle Scholar
  57. 57.
    Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/ prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411–5PubMedCrossRefGoogle Scholar
  58. 58.
    Ducloux D, Fournier V, Bresson-Vautrin C, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity. A preliminary report. Transplantation 1998; 65: 1504–6PubMedCrossRefGoogle Scholar
  59. 59.
    Wierzbicki AS. The role of lipid lowering in transplantation. Int J Clin Pract 1999; 53: 54–9PubMedGoogle Scholar
  60. 60.
    Tonstad S, Holdaas H, Gϕrbitz C, et al. Is dietary intervention effective in posttransplant hyperlipidemia? Nephrol Dial Transplant 1995; 10: 82–5PubMedGoogle Scholar
  61. 61.
    Álvarez ML, Errasti P, Gómez G, et al. Effect of atorvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplant Proc 1999; 31: 2328–9PubMedCrossRefGoogle Scholar
  62. 62.
    Pflugfelder PW, Huff M, Oskalns R, et al. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995; 14: 613–22PubMedGoogle Scholar
  63. 63.
    Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58: 245–7PubMedGoogle Scholar
  64. 64.
    Lal SM, Hewett JE, Petroski GF, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labelled crossover trial. Am J Kidney Dis 1995; 25: 616–22PubMedCrossRefGoogle Scholar
  65. 65.
    Kato T, Tokoro T, Namii Y, et al. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplant Proc 2000; 32: 331–3PubMedCrossRefGoogle Scholar
  66. 66.
    Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7PubMedCrossRefGoogle Scholar
  67. 67.
    Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398–402PubMedCrossRefGoogle Scholar
  68. 68.
    Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727–35PubMedCrossRefGoogle Scholar
  69. 69.
    Arnadottir M, Hultberg B, Wahlberg J, et al. Serum total homocysteine concentration before and after renal transplantation. Kidney Int 1998; 54: 1380–4PubMedCrossRefGoogle Scholar
  70. 70.
    Cole DE, Ross HJ, Evrovski J, et al. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem 1998; 44: 2307–12PubMedGoogle Scholar
  71. 71.
    Bostom AG, Gohh RY, Beaulieu AJ, et al. Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation 1999; 68: 257–61PubMedCrossRefGoogle Scholar
  72. 72.
    Bostom AG, Shemin D, Gohh RY, et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int 2001; 59: S246–52CrossRefGoogle Scholar
  73. 73.
    Cook RC, Tupper JK, Parker S, et al. Effect of immunosuppressive therapy, serum creatinine and time after transplantation on plasma total homocysteine in patients following heart transplantation. J Heart Lung Transplant 1995; 18(5): 420–4CrossRefGoogle Scholar
  74. 74.
    Arnadottir M, Hultberg B, Vladov V, et al. Hyperhomocy steinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509–12PubMedCrossRefGoogle Scholar
  75. 75.
    Fernandez-Miranda C, Gomez P, Diaz-Rubio P, et al. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplant 2000; 14(2): 110–4PubMedCrossRefGoogle Scholar
  76. 76.
    Ducloux D, Motte G, Challier B, et al. Serum total homocysteine and cardiovascular disease occurrence in chronic stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134–7PubMedGoogle Scholar
  77. 77.
    Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997; 127: 1089–92PubMedGoogle Scholar
  78. 78.
    Bostom AG, Shemin D, Gohh RY, et al. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 2000; 69(10): 2128–31PubMedCrossRefGoogle Scholar
  79. 79.
    Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307–13PubMedCrossRefGoogle Scholar
  80. 80.
    Arend S, Mallat M, Westendorp R, et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12: 1672–9PubMedCrossRefGoogle Scholar
  81. 81.
    Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217–22PubMedCrossRefGoogle Scholar
  82. 82.
    Zeier M, Mandelbaum A, Ritz E. Hypertension in the transplanted patient. Nephron 1998; 80: 257–68PubMedCrossRefGoogle Scholar
  83. 83.
    Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182–93PubMedCrossRefGoogle Scholar
  84. 84.
    Midtvedt K, Hartmann A, Bentdal ϕ, et al. Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living-donor transplantation. Nephrol Dial Transplant 1996; 11: 2045–9PubMedCrossRefGoogle Scholar
  85. 85.
    Pérez Fontán M, Rodríguez-Carmona A, Garcia Falcón T, et al. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999; 33: 21–8PubMedCrossRefGoogle Scholar
  86. 86.
    Budde K, Waiser J, Fritsche L, et al. Hypertension in patients after renal transplantation. Transplant Proc 1997; 29: 209–11PubMedCrossRefGoogle Scholar
  87. 87.
    Brown MJ, Haydock S. Pathoaetiology, epidemiology and diagnosis of hypertension. Drugs 2000; 59Suppl. 2: 1–12PubMedCrossRefGoogle Scholar
  88. 88.
    Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and mortality in renal transplant recipients. Results from a 5 year follow-up [abstract no. A231]. Nephrol Dial Transplant 1997; 12Google Scholar
  89. 89.
    Curtis JJ. Posttransplant hypertension. Transplant Proc 1998; 30: 2009–11PubMedCrossRefGoogle Scholar
  90. 90.
    Morrison RJ, Short HD, Noon GP, et al. Hypertension after lung transplantation. J Heart Lung Transplant 1993; 12: 928–31PubMedGoogle Scholar
  91. 91.
    Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132(6): 623–9PubMedCrossRefGoogle Scholar
  92. 92.
    Van Joost T, Bos JD, Heule F, et al. Low dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988; 118(2): 183–90PubMedCrossRefGoogle Scholar
  93. 93.
    Fry L. Psoriasis: immunopathology and long-term treatment with cyclosporin. J Autoimmun 1992; 5Suppl. A: 277–83PubMedCrossRefGoogle Scholar
  94. 94.
    Bartholomeusz B, Hardy KJ, Nelson AS, et al. Modulation of nitric oxide improves cyclosporine A-induced hypertension in rats and primates. J Hum Hypertens 1998; 12: 839–44PubMedCrossRefGoogle Scholar
  95. 95.
    Farge D, Julien J. Effects of transplantation on the renin angiotensin system (RAS). J Hum Hypertens 1998; 12: 827–32PubMedCrossRefGoogle Scholar
  96. 96.
    Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13: 209–20PubMedCrossRefGoogle Scholar
  97. 97.
    Pirsch JD. Tacrolimus versus cyclosporine in kidney transplantation: five-year survival results of the US multicenter, randomized, comparative study. FK506 Kidney Transplant Study Group. Transplantation 2000; 69Suppl.: S113CrossRefGoogle Scholar
  98. 98.
    Jurewicz WA. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplant Proc 1999; 31Suppl. 7A: 64S–6SPubMedCrossRefGoogle Scholar
  99. 99.
    van Riemsdijk IC, Baan CC, Mol WM, et al. Conversion from cyclosporine to tacrolimus improves blood pressure and cholesterol levels in heart transplant recipients without affection the TGF-β system. Am soc Transpl 2000; Abstract A698Google Scholar
  100. 100.
    Vanrenterghem YFC. Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertens 1999; 8: 669–74PubMedCrossRefGoogle Scholar
  101. 101.
    Veenstra DL, Best JH, Hornberger J, et al. Incidence and longterm cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33(5): 829–39PubMedCrossRefGoogle Scholar
  102. 102.
    Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588–92PubMedCrossRefGoogle Scholar
  103. 103.
    Schulak JA, Hricik DE. Steroid withdrawal after renal transplantation. Clin Transplant 1994; 8: 211–6PubMedGoogle Scholar
  104. 104.
    Rao VK. Posttransplant medical complications. Surg Clin North Am 1998; 78: 113–32PubMedCrossRefGoogle Scholar
  105. 105.
    Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999; 58: 1011–27PubMedCrossRefGoogle Scholar
  106. 106.
    Midtvedt K, Hartmann A, Foss A, et al. Improved long-term graft function and fewer rejection episodes in hypertensive renal transplant patients treated with nifedipine as compared to lisinopril [abstract no. A3728]. J Am Soc Nephrol 1999; 10Google Scholar
  107. 107.
    Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43(2): 419–25PubMedCrossRefGoogle Scholar
  108. 108.
    Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999 Jun; 33(6): 680–2PubMedCrossRefGoogle Scholar
  109. 109.
    Krahenbuhl S. Menafoglio A. Giostra E, et al. Serious interaction between mibefradil and tacrolimus. Transplantation 1998; 66: 1113–5PubMedCrossRefGoogle Scholar
  110. 110.
    Ocran KW, Plauth M, Mai I, et al. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation. Z Gastroenterol 1999; 37: 1025–8PubMedGoogle Scholar
  111. 111.
    Seifeldin RA, Marcos-Alvarez A, Gordon FD, et al. Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother 1997; 31: 571–5PubMedGoogle Scholar
  112. 112.
    Iwasaki K, Matsuda H, Nagase K, et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993; 82: 209–16PubMedGoogle Scholar
  113. 113.
    Brockmoller J, Neumayer HH, Wagner K, et al. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990; 38(3): 237–42PubMedCrossRefGoogle Scholar
  114. 114.
    Kaijser M, Johnsson C, Zezina L, et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant 1997; 11: 577–81PubMedGoogle Scholar
  115. 115.
    Elliott WJ. Traditional drug therapy of hypertension in transplant recipients. J Hum Hypertens 1998; 12: 845–9PubMedCrossRefGoogle Scholar
  116. 116.
    Hernandez D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58: 889–97PubMedCrossRefGoogle Scholar
  117. 117.
    Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507–13PubMedCrossRefGoogle Scholar
  118. 118.
    Zezina L, Larssen E, Fellström B. Candesartan cilexitil reduces graft arteriosclerosis in aortic transplantation model in rat. Transpl Immunol 2001. In PressGoogle Scholar
  119. 119.
    Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus: The role of immunosuppression. Drug Saf 1997; 16: 242–57PubMedCrossRefGoogle Scholar
  120. 120.
    Jindal RM. Posttransplant diabetes mellitus — a review. Transplantation 1994; 58: 1289–98PubMedGoogle Scholar
  121. 121.
    Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376–81PubMedCrossRefGoogle Scholar
  122. 122.
    Hathaway DK, Tolley EA, Blakely ML, et al. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993; 7: 330–8PubMedGoogle Scholar
  123. 123.
    Arner P, Gunnarsson R, Blomdahl S, et al. Some characteristics of steroid diabetes — a study in renal transplant recipients receiving high dose corticosteroid therapy. Diabetes Care 1983; 6: 23PubMedCrossRefGoogle Scholar
  124. 124.
    Jindal RM, Dubernard J-M. Towards a specific immunosuppression for pancreas and islet grafts. Clin Transplant 2000; 14: 242–5PubMedCrossRefGoogle Scholar
  125. 125.
    Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23 Suppl. 1: S4Google Scholar
  126. 126.
    Miles AMV, Sumrani NB, Horowitz R, et al. Diabetes after renal transplantation. As deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380–4Google Scholar
  127. 127.
    Friedman EA, Shyh TP, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196–202PubMedCrossRefGoogle Scholar
  128. 128.
    Després J-P, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–7PubMedCrossRefGoogle Scholar
  129. 129.
    Pyörälä M, Miettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policeman Study. Circulation 1998; 98: 398–404PubMedCrossRefGoogle Scholar
  130. 130.
    Kneteman NM, Lakey JRT, Wagner T, et al. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996; 61: 1206–10PubMedCrossRefGoogle Scholar
  131. 131.
    Hjelmesæth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979–83PubMedCrossRefGoogle Scholar
  132. 132.
    Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporinetreated renal transplant recipients. Transplantation 1991; 51: 374–7PubMedCrossRefGoogle Scholar
  133. 133.
    Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34: 1–13PubMedCrossRefGoogle Scholar
  134. 134.
    Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318: 1104–7PubMedCrossRefGoogle Scholar
  135. 135.
    Morris-Stiff G. Prospective randomized study comparing FK506 (Prograf) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Transplant Proc 1999; 30: 288–92Google Scholar
  136. 136.
    Miller J. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875–80PubMedCrossRefGoogle Scholar
  137. 137.
    Forsythe J. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. European Multicentre Tacrolimus/MMF Study Group. Transplant Proc 1999; 31Suppl. 7A: 69S–71SPubMedCrossRefGoogle Scholar
  138. 138.
    Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc 1998; 30: 1257–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of Medical SciencesUniversity HospitalUPPSALASweden

Personalised recommendations